Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
281K
Short interest
settlement 2026-10-15
1.0
Days to cover
-0.1 days vs prior
48.5%
Short share of volume
2026-11-02
153
Fails to deliver
settlement 2026-10-14
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CVKD is 281,405 shares, up 162,605 shares over the last month. Over the last 48 readings it ranged from 9,933 shares (30 September 2025) to 281,405 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 310K shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cvkd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 281,405 | +165.6% | 310,361 | 1.00 |
| 2026-09-30 | 105,945 | -10.8% | 98,169 | 1.08 |
| 2026-09-15 | 118,800 | +36.8% | 225,284 | 1.00 |
| 2026-08-31 | 86,862 | +33.5% | 1,998,665 | 1.00 |
| 2026-08-14 | 65,083 | +6.5% | 36,140 | 1.80 |
| 2026-07-31 | 61,103 | +9.8% | 52,729 | 1.16 |
| 2026-07-15 | 55,656 | -32.1% | 117,234 | 1.00 |
| 2026-06-30 | 82,016 | +13.5% | 67,530 | 1.21 |
| 2026-06-15 | 72,278 | +5.3% | 78,561 | 1.00 |
| 2026-05-29 | 68,650 | -3.2% | 55,563 | 1.24 |
| 2026-05-15 | 70,928 | +30.5% | 70,442 | 1.01 |
| 2026-04-30 | 54,350 | +24.9% | 69,503 | 1.00 |
| 2026-04-15 | 43,509 | +48.0% | 29,003 | 1.50 |
| 2026-03-31 | 29,406 | -60.6% | 53,073 | 1.00 |
| 2026-03-13 | 74,726 | -32.3% | 40,693 | 1.84 |
| 2026-02-27 | 110,378 | +95.5% | 66,749 | 1.65 |
| 2026-02-13 | 56,472 | -20.8% | 31,172 | 1.81 |
| 2026-01-30 | 71,276 | +22.1% | 45,834 | 1.56 |
| 2026-01-15 | 58,362 | +15.7% | 62,337 | 1.00 |
| 2025-12-31 | 50,444 | -18.2% | 83,684 | 1.00 |
| 2025-12-15 | 61,671 | +84.0% | 75,114 | 1.00 |
| 2025-11-28 | 33,512 | +20.8% | 19,886 | 1.69 |
| 2025-11-14 | 27,737 | -2.3% | 15,332 | 1.81 |
| 2025-10-31 | 28,386 | +53.7% | 25,586 | 1.11 |
| 2025-10-15 | 18,468 | +85.9% | 25,120 | 1.00 |
| 2025-09-30 | 9,933 | -15.1% | 31,486 | 1.00 |
| 2025-09-15 | 11,693 | +3.3% | 22,441 | 1.00 |
| 2025-08-29 | 11,321 | -36.5% | 29,776 | 1.00 |
| 2025-08-15 | 17,823 | -45.9% | 36,051 | 1.00 |
| 2025-07-31 | 32,956 | +62.6% | 25,238 | 1.31 |
| 2025-07-15 | 20,271 | +1.7% | 32,540 | 1.00 |
| 2025-06-30 | 19,939 | +1.5% | 37,472 | 1.00 |
| 2025-06-13 | 19,643 | -38.8% | 26,399 | 1.00 |
| 2025-05-30 | 32,088 | -37.6% | 14,228 | 2.26 |
| 2025-05-15 | 51,444 | +120.4% | 29,935 | 1.72 |
| 2025-04-30 | 23,345 | -27.3% | 17,058 | 1.37 |
| 2025-04-15 | 32,088 | -38.4% | 22,262 | 1.44 |
| 2025-03-31 | 52,078 | +1.3% | 28,108 | 1.85 |
| 2025-03-14 | 51,436 | +74.4% | 45,144 | 1.14 |
| 2025-02-28 | 29,495 | -28.9% | 50,055 | 1.00 |
| 2025-02-14 | 41,482 | +42.7% | 33,214 | 1.25 |
| 2025-01-31 | 29,065 | -41.7% | 53,463 | 1.00 |
| 2025-01-15 | 49,842 | -30.8% | 53,322 | 1.00 |
| 2024-12-31 | 71,999 | -15.6% | 80,950 | 1.00 |
| 2024-12-13 | 85,317 | +5.7% | 72,094 | 1.18 |
| 2024-11-29 | 80,683 | +22.2% | 49,698 | 1.62 |
| 2024-11-15 | 66,017 | +67.2% | 91,758 | 1.00 |
| 2024-10-31 | 39,480 | +65.3% | 75,126 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CVKD volume is 48.5%, up 8.6 points over the last five sessions. Over the last 30 readings it ranged from 15.0% (23 October 2026) to 96.5% (30 October 2026). The latest reading is in line with the 30-session average of 48.7%, on 185K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 90K | 185K | 48.5% | 0 |
| 2026-10-30 | 49K | 50K | 96.5% | 0 |
| 2026-10-29 | 10K | 37K | 27.1% | 0 |
| 2026-10-28 | 11K | 30K | 38.4% | 0 |
| 2026-10-27 | 31K | 42K | 74.7% | 0 |
| 2026-10-26 | 14K | 35K | 40.0% | 0 |
| 2026-10-23 | 3K | 20K | 15.0% | 0 |
| 2026-10-22 | 3K | 12K | 24.0% | 0 |
| 2026-10-21 | 7K | 19K | 35.4% | 0 |
| 2026-10-20 | 5K | 33K | 16.3% | 0 |
| 2026-10-19 | 54K | 100K | 53.7% | 0 |
| 2026-10-16 | 79K | 100K | 79.4% | 201 |
| 2026-10-15 | 40K | 72K | 55.6% | 7,500 |
| 2026-10-14 | 107K | 172K | 62.6% | 3,559 |
| 2026-10-13 | 144K | 253K | 57.1% | 41,318 |
| 2026-10-12 | 45K | 78K | 58.0% | 2,623 |
| 2026-10-09 | 28K | 44K | 62.5% | 14,420 |
| 2026-10-08 | 91K | 157K | 58.0% | 9,551 |
| 2026-10-07 | 253K | 495K | 51.1% | 25,770 |
| 2026-10-06 | 35K | 61K | 56.8% | 0 |
| 2026-10-05 | 28K | 48K | 57.3% | 7,167 |
| 2026-10-02 | 50K | 116K | 43.0% | 2,140 |
| 2026-10-01 | 32K | 53K | 60.7% | 2,100 |
| 2026-09-30 | 5K | 13K | 38.1% | 0 |
| 2026-09-29 | 11K | 25K | 43.3% | 0 |
| 2026-09-28 | 14K | 42K | 33.8% | 0 |
| 2026-09-25 | 21K | 80K | 26.3% | 0 |
| 2026-09-24 | 39K | 71K | 55.1% | 0 |
| 2026-09-23 | 96K | 165K | 58.5% | 0 |
| 2026-09-22 | 17K | 49K | 33.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in CVKD is 153 shares, down 18 shares over the last settlement date. Over the last 30 readings it ranged from 13 shares (1 June 2026) to 431,035 shares (1 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 153 | $1.00 | $153 |
| 2026-10-08 | 171 | $0.97 | $166 |
| 2026-10-06 | 471 | $0.95 | $447 |
| 2026-09-11 | 786 | $1.18 | $927 |
| 2026-09-10 | 42 | $1.19 | $50 |
| 2026-09-08 | 2,093 | $1.22 | $3K |
| 2026-09-03 | 63 | $1.33 | $84 |
| 2026-09-01 | 431,035 | $1.75 | $754K |
| 2026-08-24 | 74 | $1.61 | $119 |
| 2026-08-10 | 839 | $1.95 | $2K |
| 2026-07-28 | 1,956 | $2.06 | $4K |
| 2026-07-15 | 965 | $2.42 | $2K |
| 2026-07-02 | 976 | $3.17 | $3K |
| 2026-06-30 | 188 | $3.02 | $568 |
| 2026-06-29 | 730 | $3.05 | $2K |
| 2026-06-26 | 2,057 | $2.86 | $6K |
| 2026-06-24 | 20 | $3.06 | $61 |
| 2026-06-17 | 320 | $3.04 | $973 |
| 2026-06-16 | 790 | $3.33 | $3K |
| 2026-06-15 | 12,909 | $3.70 | $48K |
| 2026-06-12 | 128 | $4.03 | $516 |
| 2026-06-11 | 6,077 | $4.14 | $25K |
| 2026-06-10 | 44 | $3.95 | $174 |
| 2026-06-03 | 16,270 | $4.35 | $71K |
| 2026-06-01 | 13 | $4.91 | $64 |
| 2026-05-29 | 1,765 | $5.10 | $9K |
| 2026-05-22 | 2,201 | $5.17 | $11K |
| 2026-05-19 | 120 | $4.82 | $578 |
| 2026-05-18 | 33 | $5.10 | $168 |
| 2026-04-30 | 1,394 | $5.59 | $8K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CVKD in the last 90 days. The most recent filings are listed below. Latest filing: Pham Quang X (Chairman and CEO) on 2026-06-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Pham Quang X | Chairman and CEO | Sell | 7K | $3.03 | $22K | 99K |
| 2026-06-26 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 9K | $3.05 | $28K | 106K |
| 2026-06-25 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 2K | $3.00 | $6K | 115K |
| 2026-06-23 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 2K | $3.20 | $7K | 117K |
| 2026-06-22 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 9K | $3.55 | $33K | 119K |
| 2026-06-17 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 513 | $3.16 | $2K | 129K |
| 2026-06-16 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 4K | $3.18 | $11K | 129K |
| 2026-06-15 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 4K | $3.58 | $13K | 133K |
| 2026-06-12 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 13K | $3.94 | $51K | 136K |
| 2026-06-11 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 1K | $4.12 | $6K | 149K |
| 2026-06-10 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 4K | $4.21 | $15K | 151K |
| 2026-06-09 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 13K | $4.06 | $53K | 154K |
| 2026-06-08 | Pham Quang X | Chairman, CEO and Interim CFO | Sell | 6K | $4.38 | $26K | 167K |
| 2026-06-05 | Pham Quang X | CEO and Chairman | Sell | 2K | $4.42 | $9K | 173K |
| 2026-06-04 | Pham Quang X | CEO and Chairman | Sell | 4K | $4.41 | $17K | 175K |
| 2026-06-03 | Pham Quang X | CEO and Chairman | Sell | 2K | $4.26 | $10K | 179K |
| 2026-06-02 | Pham Quang X | CEO and Chairman | Sell | 349 | $4.46 | $2K | 182K |
| 2026-05-29 | Pham Quang X | CEO and Chairman | Sell | 303 | $5.01 | $2K | 182K |
| 2026-05-28 | Pham Quang X | CEO and Chairman | Sell | 3K | $4.93 | $15K | 182K |
| 2026-05-22 | Pham Quang X | CEO and Chairman | Sell | 1K | $5.69 | $7K | 195K |
| 2026-05-12 | Pham Quang X | CEO and Chairman | Sell | 3K | $5.28 | $17K | 185K |
| 2026-05-11 | Pham Quang X | CEO and Chairman | Sell | 6K | $5.76 | $37K | 188K |
| 2025-12-29 | Szot Matthew K | Chief Financial Officer | Sell | 10K | $6.97 | $69K | 0 |
| 2025-10-27 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $13.99 | $25K | 10K |
| 2025-10-27 | Pham Quang X | CEO and Chairman | Sell | 1K | $13.99 | $18K | 196K |
| 2025-10-24 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $13.99 | $25K | 12K |
| 2025-10-24 | Pham Quang X | CEO and Chairman | Sell | 1K | $14.03 | $16K | 197K |
| 2025-10-13 | Pham Quang X | CEO and Chairman | Sell | 2K | $14.15 | $25K | 199K |
| 2025-10-13 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $14.07 | $25K | 14K |
| 2025-10-09 | Pham Quang X | CEO and Chairman | Sell | 2K | $14.02 | $25K | 200K |
| 2025-10-09 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $13.99 | $24K | 15K |
| 2025-10-06 | Szot Matthew K | Chief Financial Officer | Sell | 107 | $13.99 | $1K | 17K |
| 2025-10-02 | Pham Quang X | CEO and Chairman | Sell | 500 | $14.13 | $7K | 202K |
| 2025-10-01 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $13.99 | $24K | 17K |
| 2025-10-01 | Pham Quang X | CEO and Chairman | Sell | 881 | $14.01 | $12K | 203K |
| 2025-09-29 | Szot Matthew K | Chief Financial Officer | Sell | 100 | $14.00 | $1K | 19K |
| 2025-09-29 | Pham Quang X | CEO and Chairman | Sell | 419 | $14.01 | $6K | 204K |
| 2025-09-25 | Szot Matthew K | Chief Financial Officer | Sell | 11K | $14.05 | $153K | 19K |
| 2025-09-25 | Pham Quang X | CEO and Chairman | Sell | 7K | $14.09 | $96K | 204K |
| 2025-09-24 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $14.00 | $21K | 30K |
| 2025-09-24 | Pham Quang X | CEO and Chairman | Sell | 3K | $13.99 | $36K | 211K |
| 2025-08-28 | Szot Matthew K | Chief Financial Officer | Sell | 400 | $14.00 | $6K | 31K |
| 2025-08-28 | Pham Quang X | CEO and Chairman | Sell | 1K | $13.99 | $17K | 213K |
| 2025-08-27 | Szot Matthew K | Chief Financial Officer | Sell | 2K | $13.99 | $22K | 32K |
| 2025-08-27 | Pham Quang X | CEO and Chairman | Sell | 4K | $13.99 | $54K | 214K |
| 2024-04-10 | Pham Quang X | CEO and Chairman | Gift | 50K | $0.00 | $0 | 3.3M |
| 2023-10-23 | Pham Quang X | CEO and Chairman | Gift | 85K | $0.00 | $0 | 3.3M |
| 2023-10-05 | MURPHY JOHN RAYMOND | Director | Buy | 3K | $0.69 | $2K | 615K |
| 2023-10-04 | MURPHY JOHN RAYMOND | Director | Buy | 17K | $0.70 | $12K | 612K |
| 2023-09-05 | Pham Quang X | CEO and Chairman | Buy | 20K | $0.90 | $18K | 3.4M |
| 2023-09-05 | Pham Quang X | CEO and Chairman | Buy | 20K | $0.91 | $18K | 3.4M |
| 2023-09-01 | Pham Quang X | CEO and Chairman | Buy | 10K | $0.84 | $8K | 3.4M |
| 2023-09-01 | Pham Quang X | CEO and Chairman | Buy | 10K | $0.92 | $9K | 3.4M |
| 2023-09-01 | Pham Quang X | CEO and Chairman | Buy | 20K | $0.92 | $18K | 3.4M |
| 2023-09-01 | Pham Quang X | CEO and Chairman | Buy | 20K | $0.93 | $19K | 3.3M |
| 2023-09-01 | Pham Quang X | CEO and Chairman | Buy | 10K | $0.93 | $9K | 3.3M |
| 2023-03-21 | MURPHY JOHN RAYMOND | Director | Buy | 10K | $1.39 | $14K | 595K |
| 2023-03-16 | MURPHY JOHN RAYMOND | Director | Buy | 20K | $1.67 | $33K | 575K |
| 2023-02-10 | Pham Quang X | CEO and Chairman | Grant | 25K | $1.94 | $49K | 3.3M |
| 2023-01-24 | MURPHY JOHN RAYMOND | Director | Conversion | 515K | price not stated in the filing | not stated | 555K |
| 2023-01-24 | Szot Matthew K | Chief Financial Officer | Grant | 50K | $0.00 | $0 | 500K |
| 2023-01-24 | WILSON GLYNN | Director | Conversion | 50K | price not stated in the filing | not stated | 50K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON20 Form 144 notices on file for CVKD worth $707K at the prices reported; 0 in the last 90 days worth $0. Latest: MATTHEW K SZOT filed on 2025-12-29 to sell 9,933 shares ($74K) from 2025-12-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-29 | MATTHEW K SZOTOfficer | 10K | $74K | 0.479% | 2025-12-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-27 | MATTHEW SZOTOfficer | 2K | $25K | 0.088% | 2025-10-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-27 | Quang X. PhamOfficer | 1K | $18K | 0.064% | 2025-10-27 | Merrill Lynch |
| 2025-10-24 | MATTHEW SZOTOfficer | 2K | $25K | 0.088% | 2025-10-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-24 | Quang X. PhamOfficer | 1K | $16K | 0.055% | 2025-10-24 | Merrill Lynch |
| 2025-10-14 | MATTHEW SZOTOfficer | 2K | $25K | 0.088% | 2025-10-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-14 | Quang X. PhamOfficer | 2K | $25K | 0.088% | 2025-10-13 | Merrill Lynch |
| 2025-10-09 | MATTHEW SZOTOfficer | 2K | $24K | 0.083% | 2025-10-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-09 | Quang X. PhamOfficer | 2K | $25K | 0.088% | 2025-10-09 | Merrill Lynch |
| 2025-10-06 | MATTHEW SZOTOfficer | 107 | $2K | 0.005% | 2025-10-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-02 | Quang X. PhamOfficer | 500 | $7K | 0.024% | 2025-10-02 | Merrill Lynch |
| 2025-10-01 | MATTHEW SZOTOfficer | 2K | $24K | 0.083% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-01 | Quang X. PhamOfficer | 881 | $12K | 0.043% | 2025-10-01 | Merrill Lynch |
| 2025-09-29 | Quang X. PhamOfficer | 7K | $96K | 0.332% | 2025-09-25 | Merrill Lynch |
| 2025-09-29 | MATTHEW SZOTOfficer | 100 | $1K | 0.005% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | Quang X. PhamOfficer | 419 | $6K | 0.020% | 2025-09-29 | Merrill Lynch |
| 2025-09-25 | MATTHEW SZOTOfficer | 11K | $150K | 0.533% | 2025-09-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-25 | Quang X. PhamOfficer | 7K | $96K | 0.332% | 2025-09-24 | Merrill Lynch |
| 2025-09-24 | MATTHEW SZOTOfficer | 2K | $21K | 0.073% | 2025-09-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-24 | Quang PhamOfficer | 3K | $36K | 0.126% | 2025-09-24 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of CVKD in its latest filing, on Schedule 13G (passive). The holder is The PNC Financial Services Group, Inc. at 8.1% of the class (233,219 shares), filed 2026-08-07 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | The PNC Financial Services Group, Inc.parent holding company | 233K | 8.1% | 2026-06-30 |
What this page is
Cadrenal Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cadrenal Therapeutics (CVKD), SEC CIK 1937993, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 1937993Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CVKD is sold short?
281,405 shares were held short at the 2026-10-15 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CVKD's daily short volume?
On 2026-11-02, 89,709 of the 184,906 CVKD shares reported to FINRA were sold short, 48.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CVKD have fails to deliver?
The SEC's latest file shows 153 CVKD shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are CVKD insiders buying or selling?
No open-market insider trades were reported for CVKD in the last 90 days. The most recent filings are listed below. Latest filing: Pham Quang X (Chairman and CEO) on 2026-06-29.
Have CVKD insiders filed to sell?
20 Form 144 notices on file for CVKD worth $707K at the prices reported; 0 in the last 90 days worth $0. Latest: MATTHEW K SZOT filed on 2025-12-29 to sell 9,933 shares ($74K) from 2025-12-29.
Who owns 5% or more of CVKD?
1 holder reports 5% or more of CVKD in its latest filing, on Schedule 13G (passive). The holder is The PNC Financial Services Group, Inc. at 8.1% of the class (233,219 shares), filed 2026-08-07 for an event on 2026-06-30.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.